ArticleFrontiers in endocrinology2023
Establishment of papillary thyroid cancer organoid lines from clinical specimens.
Article in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review on the culture methods and applications of 3D tumoroids for cancer research and personalized medicine.Cellular oncology (Dordrecht, Netherlands) · 2025Pooled it
- The Application of 3D Cell Culture in Thyroid Cancer.Annals of biomedical engineering · 2026Review
- Stattic engineering M2 macrophage-derived exosomes mediate autophagy and immune reprogramming for secondary hyperparathyroidism.Journal of advanced research · 2026Article
- Microfluidic-based patient-derived organoids recapitulate thyroid cancer heterogeneity and reveal NF-κB-driven maturation for precision therapy.Journal of translational medicine · 2026Article
- Genetically Engineered Cell Membrane-Coated Nanodrug for Targeted Treatment of Thyroid Cancer.Biomaterials research · 2026Article
- Dual-database Bibliometric Analysis Combined with Gephi-based Network Visualization of Artificial Intelligence Applications in the Identification and Diagnosis of Thyroid Space-occupying Lesions.Current medical imaging · 2026Article
- Modeling of Patient-Derived 3D Organoids of Thyroid Cancer: From Cells to Care.International journal of endocrinology · 2026Article
- Head and neck cancer organoids: a panoramic perspective from basic construction to clinical translation.Stem cell research & therapy · 2025Review
- Papillary Thyroid Carcinoma and Its Hormonal Effects in Women Following Surgical Removal.Cureus · 2025Review
- Review
- Organoid Technology in Precision Medicine for Head and Neck Cancer.Oncology research · 2025Review
- Development of a biomimetic thyroid acellular scaffold as a 3D platform for modeling thyroid cancer aggressiveness and drug resistance.Frontiers in bioengineering and biotechnology · 2025Article
- Organoid as a promising tool for primary liver cancer research: a comprehensive review.Cell & bioscience · 2024Review
- Article
- Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology.Experimental & molecular medicine · 2024Review
- Advanced 3D imaging and organoid bioprinting for biomedical research and therapeutic applications.Advanced drug delivery reviews · 2024Review
- Anaplastic thyroid cancer spheroids as preclinical models to test therapeutics.Journal of experimental & clinical cancer research : CR · 2024Article
- Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids.Oncogene · 2024Article
- The applications and techniques of organoids in head and neck cancer therapy.Frontiers in oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Papillary thyroid cancer (PTC) is a common malignancy of the endocrine system, and its morbidity and mortality are increasing year by year. Traditional two-dimensional culture of cell lines lacks tissue structure and is difficult to reflect the heterogeneity of tumors. The construction of mouse models is inefficient and time-consuming, which is difficult to be applied to individualized treatment on a large scale. Clinically relevant models that recapitulate the biology of their corresponding parental tumors are urgently needed. Based on clinical specimens of PTC, we have successfully established patient-derived organoids by exploring and optimizing the organoid culture system. These organoids have been cultured stably for more than 5 passages and successfully cryopreserved and retried. Histopathological and genome analysis revealed a high consistency of the histological architectures as well as mutational landscapes between the matched tumors and organoids. Here, we present a fully detailed method to derive PTC organoids from clinical specimens. Using this approach, we have developed PTC organoid lines from thyroid cancer samples with a success rate of 77.6% (38/49) until now.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.